marked.bio

CD137 agonist antibody · antibody

AGEN2373

1 active trials across 3 of our biomarkers, targeting CD137. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 1 1 Phase 1/2
KRAS G12D 1 1 Phase 1/2
BRAF V600E 0 1 –

Trials

1 of 2 trials shown

  1. Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

    Recruiting Phase 1/2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2025Primary completion 2028-12 NCT06782932

    AGEN2373balstilimabcyclophosphamideGVAXmKRASvax

    A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resec…

    KRAS G12CKRAS G12DPancreatic Cancer